Migraine drugs market in Latin America 2023-2027: 5-Year (2017-2021) historic industry size and analysis of 15 vendors and 7 countries - Technavio

NEW YORK, Dec. 5, 2022 /PRNewswire/ -- The migraine drugs market size in Latin America is estimated to increase by USD 82.31 million from 2022 to 2027, with an accelerated CAGR of 5.82%, according to a recent market study by Technavio. This report also offers a 5-year historical (2017-2021) data projection of market size, segmentation, and region.

Discover some insights on market size before buying the full report. Request a free sample report.

Qualitative and quantitative analysis of vendors has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize vendors as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize vendors as dominant, leading, strong, tentative, and weak. The bargaining power of buyers and suppliers and the threat of new entrants, rivalry, and substitutes have also been analyzed and rated between LOW-HIGH to provide a holistic view of market favorability.

Find Technavio's exclusive analysis of price sensitivity, adoption lifecycle, customer purchase basket, adoption rates, and purchase criteria

• One of the core components of the customer landscape is price sensitivity, an analysis of which will help companies refine marketing strategies to gain a competitive advantage. 
• Another key aspect is price sensitivity drivers (purchases are undifferentiated, purchase is a key cost to buyers, and quality is not important), which range between LOW and NEUTRAL.
• Furthermore, market adoption rates for all regions have been covered.

The migraine drugs market in Latin America report also offers information on the criticality of inputs, R&D, CAPEX, technology, and products of 15 vendors listed below –

• Amgen Inc.
• Amneal Pharmaceuticals Inc.
• Bausch Health Co. Inc.
• Bayer AG
• Daiichi Sankyo Co. Ltd.
• Dr Reddy's Laboratories Ltd.
• Eli Lilly and Co.
• Endo International Plc
• Ethypharm SAS
• GlaxoSmithKline Plc
• H Lundbeck AS
• IntelGenx Technologies Corp.
• Klaria Pharma Holding AB
• Kowa Co. Ltd.
• OptiNose Inc.
• Pfizer Inc.
• Sanofi SA
• Teva Pharmaceutical Industries Ltd.
• UCB SA

Download a sample report 

Chart and data table on 5-year historic (2017-2021) market size, comparative analysis of segments, and Y-o-Y growth of migraine drugs market in Latin America

• The market is segmented by end-user (hospital, retail, and online) and therapy (preventive treatment and abortive treatment).
• Based on therapy, the preventive treatment segment will account for a significant share of the market's growth during the forecast period.
• Preventive treatments are aimed at reducing the frequency and severity of migraine attacks. Some of the medications that are considered effective for preventing migraines are beta-blockers, divalproex sodium, and topiramate.
• The availability of solutions, such as Cefaly and gammaCore, is expected to propel the growth of the preventive treatment segment during the forecast period.

To procure the data - Buy the report!

The increasing prevalence of migraine is notably driving the migraine drugs market  growth in Latin America

The prevalence of migraine in the region is growing significantly, which is fueling the demand for migraine drugs. Brazil has the most number of migraine patients in the region, followed by Colombia, Ecuador, Venezuela, Mexico, and Argentina. Migraine is more prevalent among women due to causes such as hormonal fluctuations. In addition, hormonal medications such as oral contraceptives may aggravate the symptoms. Thus, the rising prevalence of migraine, especially among women, will increase the demand for migraine drugs in Latin America during the forecast period.

Chart and data table on historical market size (2017-2021), historic industry size, and analysis of 15 vendors and 7 countries

The market is segmented by region (Mexico, Brazil, Argentina, Chile, and Rest of Latin America). An analysis of key leading countries has been included.

• Mexico was one of the biggest contributors to the migraine drugs market in Latin America in 2022, and it is anticipated to grow at a significant rate during the forecast period. Growth in healthcare infrastructure in Mexico will positively contribute to the growth of the migraine drugs market in the country during the forecast period. The growing population, sedentary lifestyle, and rising prevalence of neurological disorders will also drive the growth of the market during the forecast period. 
• The outbreak of COVID-19 led to a slowdown in the growth of the migraine drugs market in Mexico in the first half of 2020 due to disruption in supply chain operations during lockdowns. However, after the lifting of lockdowns and the initiation of large-scale vaccination drives, the growth momentum of the market increased. During the forecast period, the increasing adoption of e-commerce channels, the redesigning of distribution channels, and the revival of supply chain operations will foster the growth of the migraine drugs market in Mexico during the forecast period. 

For Insights on the market dynamics and segmentations, VIEW A PDF SAMPLE!

Related reports -

Migraine drugs market by end-user, type, and geography - Forecast and analysis 2022-2026 – size is estimated to increase by USD 1 billion from 2021 to 2026, with an accelerated CAGR of 5.74%, according to the recent market study by Technavio. Furthermore, this report extensively covers market segmentation by end-user (hospitals, retail, and online), type (preventive and abortive), and geography (North America, Europe, Asia, and the Rest of the World (ROW)).  To get more exclusive research insights: VIEW SUMMARY OF THE REPORT  

Narcolepsy drugs market by type and geography - Forecast and analysis 2022-2026 – size is estimated to increase by USD 1.60 billion from 2021 to 2026, with an accelerated CAGR of 9.1%, according to the recent market study by Technavio. The rising number of product launches and clinical trials is one of the key factors driving the market growth. To get more exclusive research insights: VIEW SUMMARY OF THE REPORT 

Register for a free trial today and gain instant access to 17,000+ market research reports. 
Technavio's SUBSCRIPTION platform

What are the key data covered in this migraine drugs market in Latin America report?

• CAGR of the market during the forecast period
• Detailed information on factors that will drive the growth of the migraine drugs market in Latin America between 2023 and 2027
• Precise estimation of the size of the migraine drugs market size in Latin America and its contribution to the parent market
• Accurate predictions about upcoming trends and changes in consumer behavior
• Thorough analysis of the market's competitive landscape and detailed information about vendors
• Comprehensive analysis of factors that will challenge the growth of migraine drugs market vendors in Latin America

Browse for Technavio's Health Care Market Reports

Table of Contents

1 Executive Summary

• 1.1 Market overview 
• Exhibit 01: Executive Summary – Chart on Market Overview
• Exhibit 02: Executive Summary – Data Table on Market Overview
• Exhibit 03: Executive Summary – Chart on Country Market Characteristics
• Exhibit 04: Executive Summary – Chart on Market by Geography
• Exhibit 05: Executive Summary – Chart on Market Segmentation by Therapy
• Exhibit 06: Executive Summary – Chart on Market Segmentation by End-user
• Exhibit 07: Executive Summary – Chart on Incremental Growth
• Exhibit 08: Executive Summary – Data Table on Incremental Growth
• Exhibit 09: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

• 2.1 Market ecosystem 
• Exhibit 10: Parent market
• Exhibit 11: Market Characteristics

3 Market Sizing

• 3.1 Market definition 
• Exhibit 12: Offerings of vendors included in the market definition

• 3.2 Market segment analysis 
• Exhibit 13: Market segments

• 3.3 Market size 2022

• 3.4 Market outlook: Forecast for 2022-2027 
• Exhibit 14: Chart on Latin America - Market size and forecast 2022-2027 ($ million)
• Exhibit 15: Data Table on Regional - Market size and forecast 2022-2027 ($ million)
• Exhibit 16: Chart on Latin America: Year-over-year growth 2022-2027 (%)
• Exhibit 17: Data Table on Regional - Market size and forecast 2022-2027 ($ million)

4 Historic Market Size

• 4.1 Migraine Drugs Market in Latin America 2017 - 2021 
• Exhibit 18: Historic Market Size – Data Table on Migraine Drugs Market in Latin America 2017 - 2021 ($ million)

• 4.2 Therapy Segment Analysis 2017 - 2021 
• Exhibit 19: Historic Market Size – Therapy Segment 2017 - 2021 ($ million)

• 4.3 End-User Segment Analysis 2017 - 2021 
• Exhibit 20: Historic Market Size – End-User Segment 2017 - 2021 ($ million)

• 4.4 Country Segment Analysis 2017 - 2021 
• Exhibit 21: Historic Market Size – Country Segment 2017 - 2021 ($ million)

5 Five Forces Analysis

• 5.1 Five forces summary 
• Exhibit 22: Five forces analysis - Comparison between 2022 and 2027

• 5.2 Bargaining power of buyers 
• Exhibit 23: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027

• 5.3 Bargaining power of suppliers 
• Exhibit 24: Bargaining power of suppliers – Impact of key factors in 2022 and 2027

• 5.4 Threat of new entrants 
• Exhibit 25: Threat of new entrants – Impact of key factors in 2022 and 2027

• 5.5 Threat of substitutes 
• Exhibit 26: Threat of substitutes – Impact of key factors in 2022 and 2027

• 5.6 Threat of rivalry 
• Exhibit 27: Threat of rivalry – Impact of key factors in 2022 and 2027

• 5.7 Market condition 
• Exhibit 28: Chart on Market condition - Five forces 2022 and 2027

6 Market Segmentation by Therapy

• 6.1 Market segments 
• Exhibit 29: Chart on Therapy - Market share 2022-2027 (%)
• Exhibit 30: Data Table on Therapy - Market share 2022-2027 (%)

• 6.2 Comparison by Therapy 
• Exhibit 31: Chart on Comparison by Therapy
• Exhibit 32: Data Table on Comparison by Therapy

• 6.3 Preventive treatment - Market size and forecast 2022-2027
• Exhibit 33: Chart on Preventive treatment - Market size and forecast 2022-2027 ($ million)
• Exhibit 34: Data Table on Preventive treatment - Market size and forecast 2022-2027 ($ million)
• Exhibit 35: Chart on Preventive treatment - Year-over-year growth 2022-2027 (%)
• Exhibit 36: Data Table on Preventive treatment - Year-over-year growth 2022-2027 (%)

• 6.4 Abortive treatment - Market size and forecast 2022-2027
• Exhibit 37: Chart on Abortive treatment - Market size and forecast 2022-2027 ($ million)
• Exhibit 38: Data Table on Abortive treatment - Market size and forecast 2022-2027 ($ million)
• Exhibit 39: Chart on Abortive treatment - Year-over-year growth 2022-2027 (%)
• Exhibit 40: Data Table on Abortive treatment - Year-over-year growth 2022-2027 (%)

• 6.5 Market opportunity by Therapy 
• Exhibit 41: Market opportunity by Therapy ($ million)

7 Market Segmentation by End-user

• 7.1 Market segments 
• Exhibit 42: Chart on End-user - Market share 2022-2027 (%)
• Exhibit 43: Data Table on End-user - Market share 2022-2027 (%)

• 7.2 Comparison by End-user 
• Exhibit 44: Chart on Comparison by End-user
• Exhibit 45: Data Table on Comparison by End-user

• 7.3 Hospital - Market size and forecast 2022-2027 
• Exhibit 46: Chart on Hospital - Market size and forecast 2022-2027 ($ million)
• Exhibit 47: Data Table on Hospital - Market size and forecast 2022-2027 ($ million)
• Exhibit 48: Chart on Hospital - Year-over-year growth 2022-2027 (%)
• Exhibit 49: Data Table on Hospital - Year-over-year growth 2022-2027 (%)

• 7.4 Retail - Market size and forecast 2022-2027 
• Exhibit 50: Chart on Retail - Market size and forecast 2022-2027 ($ million)
• Exhibit 51: Data Table on Retail - Market size and forecast 2022-2027 ($ million)
• Exhibit 52: Chart on Retail - Year-over-year growth 2022-2027 (%)
• Exhibit 53: Data Table on Retail - Year-over-year growth 2022-2027 (%)

• 7.5 Online - Market size and forecast 2022-2027 
• Exhibit 54: Chart on Online - Market size and forecast 2022-2027 ($ million)
• Exhibit 55: Data Table on Online - Market size and forecast 2022-2027 ($ million)
• Exhibit 56: Chart on Online - Year-over-year growth 2022-2027 (%)
• Exhibit 57: Data Table on Online - Year-over-year growth 2022-2027 (%)

• 7.6 Market opportunity by End-user 
• Exhibit 58: Market opportunity by End-user ($ million)

8 Customer Landscape

• 8.1 Customer landscape overview 
• Exhibit 59: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

• 9.1 Geographic segmentation 
• Exhibit 60: Chart on Market share by geography - 2022-2027 (%)
• Exhibit 61: Data Table on Market share by geography - 2022-2027 (%)

• 9.2 Geographic comparison 
• Exhibit 62: Chart on Geographic comparison
• Exhibit 63: Data Table on Geographic comparison

• 9.3 Mexico - Market size and forecast 2022-2027 
• Exhibit 64: Chart on Mexico - Market size and forecast 2022-2027 ($ million)
• Exhibit 65: Data Table on Mexico - Market size and forecast 2022-2027 ($ million)
• Exhibit 66: Chart on Mexico - Year-over-year growth 2022-2027 (%)
• Exhibit 67: Data Table on Mexico - Year-over-year growth 2022-2027 (%)

• 9.4 Brazil - Market size and forecast 2022-2027 
• Exhibit 68: Chart on Brazil - Market size and forecast 2022-2027 ($ million)
• Exhibit 69: Data Table on Brazil - Market size and forecast 2022-2027 ($ million)
• Exhibit 70: Chart on Brazil - Year-over-year growth 2022-2027 (%)
• Exhibit 71: Data Table on Brazil - Year-over-year growth 2022-2027 (%)

• 9.5 Argentina - Market size and forecast 2022-2027 
• Exhibit 72: Chart on Argentina - Market size and forecast 2022-2027 ($ million)
• Exhibit 73: Data Table on Argentina - Market size and forecast 2022-2027 ($ million)
• Exhibit 74: Chart on Argentina - Year-over-year growth 2022-2027 (%)
• Exhibit 75: Data Table on Argentina - Year-over-year growth 2022-2027 (%)

• 9.6 Chile - Market size and forecast 2022-2027 
• Exhibit 76: Chart on Chile - Market size and forecast 2022-2027 ($ million)
• Exhibit 77: Data Table on Chile - Market size and forecast 2022-2027 ($ million)
• Exhibit 78: Chart on Chile - Year-over-year growth 2022-2027 (%)
• Exhibit 79: Data Table on Chile - Year-over-year growth 2022-2027 (%)

• 9.7 Rest of Latin America - Market size and forecast 2022-2027
• Exhibit 80: Chart on Rest of Latin America - Market size and forecast 2022-2027 ($ million)
• Exhibit 81: Data Table on Rest of Latin America - Market size and forecast 2022-2027 ($ million)
• Exhibit 82: Chart on Rest of Latin America - Year-over-year growth 2022-2027 (%)
• Exhibit 83: Data Table on Rest of Latin America - Year-over-year growth 2022-2027 (%)

• 9.8 Market opportunity by geography 
• Exhibit 84: Market opportunity by geography ($ million)

10 Drivers, Challenges, and Trends

• 10.1 Market drivers

• 10.2 Market challenges

• 10.3 Impact of drivers and challenges 
• Exhibit 85: Impact of drivers and challenges in 2022 and 2027

• 10.4 Market trends

11 Vendor Landscape

• 11.1 Overview

• 11.2 Vendor landscape 
• Exhibit 86: Overview on Criticality of inputs and Factors of differentiation

• 11.3 Landscape disruption 
• Exhibit 87: Overview on factors of disruption

• 11.4 Industry risks 
• Exhibit 88: Impact of key risks on business

12 Vendor Analysis

• 12.1 Vendors covered 
• Exhibit 89: Vendors covered

• 12.2 Market positioning of vendors 
• Exhibit 90: Matrix on vendor position and classification

• 12.3 AbbVie Inc. 
• Exhibit 91: AbbVie Inc. - Overview
• Exhibit 92: AbbVie Inc. - Product / Service
• Exhibit 93: AbbVie Inc. - Key offerings

• 12.4 Amgen Inc. 
• Exhibit 94: Amgen Inc. - Overview
• Exhibit 95: Amgen Inc. - Product / Service
• Exhibit 96: Amgen Inc. - Key offerings

• 12.5 Amneal Pharmaceuticals Inc. 
• Exhibit 97: Amneal Pharmaceuticals Inc. - Overview
• Exhibit 98: Amneal Pharmaceuticals Inc. - Business segments
• Exhibit 99: Amneal Pharmaceuticals Inc. - Key news
• Exhibit 100: Amneal Pharmaceuticals Inc. - Key offerings
• Exhibit 101: Amneal Pharmaceuticals Inc. - Segment focus

• 12.6 Bayer AG 
• Exhibit 102: Bayer AG - Overview
• Exhibit 103: Bayer AG - Business segments
• Exhibit 104: Bayer AG - Key offerings
• Exhibit 105: Bayer AG - Segment focus

• 12.7 Daiichi Sankyo Co. Ltd. 
• Exhibit 106: Daiichi Sankyo Co. Ltd. - Overview
• Exhibit 107: Daiichi Sankyo Co. Ltd. - Business segments
• Exhibit 108: Daiichi Sankyo Co. Ltd. - Key news
• Exhibit 109: Daiichi Sankyo Co. Ltd. - Key offerings
• Exhibit 110: Daiichi Sankyo Co. Ltd. - Segment focus

• 12.8 Eli Lilly and Co. 
• Exhibit 111: Eli Lilly and Co. - Overview
• Exhibit 112: Eli Lilly and Co. - Product / Service
• Exhibit 113: Eli Lilly and Co. - Key offerings

• 12.9 Endo International Plc 
• Exhibit 114: Endo International Plc - Overview
• Exhibit 115: Endo International Plc - Business segments
• Exhibit 116: Endo International Plc - Key news
• Exhibit 117: Endo International Plc - Key offerings
• Exhibit 118: Endo International Plc - Segment focus

• 12.10 GlaxoSmithKline Plc 
• Exhibit 119: GlaxoSmithKline Plc - Overview
• Exhibit 120: GlaxoSmithKline Plc - Business segments
• Exhibit 121: GlaxoSmithKline Plc - Key offerings
• Exhibit 122: GlaxoSmithKline Plc - Segment focus

• 12.11 H Lundbeck AS 
• Exhibit 123: H Lundbeck AS - Overview
• Exhibit 124: H Lundbeck AS - Product / Service
• Exhibit 125: H Lundbeck AS - Key offerings

• 12.12 IntelGenx Technologies Corp. 
• Exhibit 126: IntelGenx Technologies Corp. - Overview
• Exhibit 127: IntelGenx Technologies Corp. - Product / Service
• Exhibit 128: IntelGenx Technologies Corp. - Key offerings

• 12.13 Klaria Pharma Holding AB 
• Exhibit 129: Klaria Pharma Holding AB - Overview
• Exhibit 130: Klaria Pharma Holding AB - Product / Service
• Exhibit 131: Klaria Pharma Holding AB - Key offerings

• 12.14 Kowa Co. Ltd. 
• Exhibit 132: Kowa Co. Ltd. - Overview
• Exhibit 133: Kowa Co. Ltd. - Product / Service
• Exhibit 134: Kowa Co. Ltd. - Key offerings

• 12.15 Pfizer Inc. 
• Exhibit 135: Pfizer Inc. - Overview
• Exhibit 136: Pfizer Inc. - Product / Service
• Exhibit 137: Pfizer Inc. - Key news
• Exhibit 138: Pfizer Inc. - Key offerings

• 12.16 Teva Pharmaceutical Industries Ltd. 
• Exhibit 139: Teva Pharmaceutical Industries Ltd. - Overview
• Exhibit 140: Teva Pharmaceutical Industries Ltd. - Business segments
• Exhibit 141: Teva Pharmaceutical Industries Ltd. - Key news
• Exhibit 142: Teva Pharmaceutical Industries Ltd. - Key offerings
• Exhibit 143: Teva Pharmaceutical Industries Ltd. - Segment focus

• 12.17 UCB SA 
• Exhibit 144: UCB SA - Overview
• Exhibit 145: UCB SA - Product / Service
• Exhibit 146: UCB SA - Key offerings

13 Appendix

• 13.1 Scope of the report

• 13.2 Inclusions and exclusions checklist 
• Exhibit 147: Inclusions checklist
• Exhibit 148: Exclusions checklist

• 13.3 Currency conversion rates for US$ 
• Exhibit 149: Currency conversion rates for US$

• 13.4 Research methodology 
• Exhibit 150: Research methodology
• Exhibit 151: Validation techniques employed for market sizing
• Exhibit 152: Information sources

• 13.5 List of abbreviations 
• Exhibit 153: List of abbreviations

About Us
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contact
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/

SOURCE Technavio

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED